2.10. Gene Expression
Tumors, tumor, colorectal cancer
TUMORS, LIVER METASTASIS, TUMOR, COLORECTAL CANCER
RNAseq was performed on 31 tumor tissue specimens from 29 patients. Only the 22 specimens originating from liver metastasis at baseline (prior treatment) were used for the differential expression analysis. This approach was chosen to mitigate potential noise in the analysis that could arise from incorporating tissues obtained from disparate locations (Next, we performed a pathway enrichment analysis using a webtool “Next, we used the same approach to identify pathways directly linked to rapid progression after regorafenib treatment. Patients were categorized into two groups according to their PFS: the “High” group comprised those with PFS ≥ 3 months, while the “Low” group encompassed patients with PFS < 3 months. One pathway, adherens junction, was identified as significantly enriched with a false discovery rate (FDR) of 0.01 in the “Low” group.In 2015, a consensus molecular subtypes (CMS) was developed based on expression data to classify colorectal cancer patients with clear biological and clinical interpretability [Finally, when we look at the distribution of CMS within the Response Evaluation Criteria in Solid Tumors (RECIST) lesion response groups, the proportion of CMS4 was more prevalent in ARES (2 out of 7, 28.6%) and IRES (3 out of 5, 60%) lesions compared to stable lesions (0 out of 7, 0%) (